Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique

Hui-ming Huang, Douglas E. Laux, Brian C. Hamlin, Phuong Tran, Hoa Tran, Dennis B. Lubahn

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.

Original languageEnglish (US)
Pages (from-to)1030-1034
Number of pages5
JournalCancer Research
Volume57
Issue number6
StatePublished - 1997
Externally publishedYes

Fingerprint

DNA Methylation
Genetic Markers
Methylation
Breast Neoplasms
Tumor Suppressor Genes
DNA
Wilms' Tumor Genes
Nucleic Acid Databases
Sequence Analysis
Carcinogenesis
Breast
Databases
Polymerase Chain Reaction
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. / Huang, Hui-ming; Laux, Douglas E.; Hamlin, Brian C.; Tran, Phuong; Tran, Hoa; Lubahn, Dennis B.

In: Cancer Research, Vol. 57, No. 6, 1997, p. 1030-1034.

Research output: Contribution to journalArticle

Huang, Hui-ming ; Laux, Douglas E. ; Hamlin, Brian C. ; Tran, Phuong ; Tran, Hoa ; Lubahn, Dennis B. / Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. In: Cancer Research. 1997 ; Vol. 57, No. 6. pp. 1030-1034.
@article{8cec8ad66f844ac497282ce7c7706802,
title = "Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique",
abstract = "We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90{\%} (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.",
author = "Hui-ming Huang and Laux, {Douglas E.} and Hamlin, {Brian C.} and Phuong Tran and Hoa Tran and Lubahn, {Dennis B.}",
year = "1997",
language = "English (US)",
volume = "57",
pages = "1030--1034",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique

AU - Huang, Hui-ming

AU - Laux, Douglas E.

AU - Hamlin, Brian C.

AU - Tran, Phuong

AU - Tran, Hoa

AU - Lubahn, Dennis B.

PY - 1997

Y1 - 1997

N2 - We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.

AB - We have developed a PCR-based method, called methylation-sensitive restriction fingerprinting (MSRF), to screen changes in DNA methylation in breast carcinoma. Two hypermethylation-containing fragments, HBC-1 (for 'hypermethylation in breast cancer') and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. Nucleotide sequence analysis revealed no significant matches between the sequence of HBC-1 and the known sequences in the GenBank database, whereas the sequence of HBC-2 matched the upstream region of an antisense WTI (Wilms' tumor suppressor gene) promoter. The methylation status in the breast tumor DNA from this patient was confirmed by Southern hybridization using HBC-1 and HBC-2 as probes, respectively. Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. This study demonstrates that MSRF provides a useful means for screening aberrant changes in DNA methylation during tumorigenesis. The commonly methylated fragments identified by MSRF could potentially supplement pathological markers currently used for cancers and additionally lead to the discovery of novel methylated tumor suppressor genes.

UR - http://www.scopus.com/inward/record.url?scp=0030888263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030888263&partnerID=8YFLogxK

M3 - Article

C2 - 9067264

AN - SCOPUS:0030888263

VL - 57

SP - 1030

EP - 1034

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -